One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Pseudo-AKI associated with targeted anti-cancer agents—the truth is in the eye of the filtration marker
Thomas Vanhoutte, Ben Sprangers
doi : 10.1093/ckj/sfad011
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 603–610
Besides true acute kidney injury (AKI), the occurrence of pseudo-AKI has been associated with several targeted agents. To improve the management of cancer patients treated with targeted agents, we need to be aware of this and use diagnostic approaches to differentiate between pseudo-AKI and AKI.
Obesity-related glomerulopathy in children: connecting pathophysiology to clinical care
Guneive Mangat, Nikhil Nair, Oren Barat, Brian Abboud, Priya Pais, Sumedha Bagga, Rupesh Raina
doi : 10.1093/ckj/sfac233
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 611–618
Obesity has continued to emerge as a worldwide pandemic and has been associated with a significant increase in associated comorbidities.
Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications
Artemios G Karagiannidis, Marieta P Theodorakopoulou, Charles J Ferro, Alberto Ortiz, Maria Jose Soler, Jean-Michel Halimi, Andrzej Januszewicz, Alexandre Persu, Reinhold Kreutz, Pantelis Sarafidis
doi : 10.1093/ckj/sfac235
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 619–634
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first identified in December 2019 and emerged into an ongoing global pandemic.
A review of supportive care for older people with advanced chronic kidney disease
Ted J FitzGerald, Hanneke Joosten, Marjolijn van Buren, Katie Vinen, Edwina A Brown
doi : 10.1093/ckj/sfac256
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 635–646
Supportive care (SC) is a multidimensional and person-centred approach to managing advanced CKD that engages the person and their caregivers in shared decision making from the outset.
Plant-based diets for CKD patients: fascinating, trendy, but feasible? A green nephrology perspective
Massimo Torreggiani, Antioco Fois, Françoise Lippi, Rossella Attini, Elisa Longhitano, Ida Matarazzo, Bianca Masturzo, Gianfranca Cabiddu, Elisabetta Versino, Giorgina Barbara Piccoli
doi : 10.1093/ckj/sfac267
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 647–661
Climate change is inducing us to rethink our way of life. There is widespread awareness that we need to adopt environmentally friendly approaches and reduce the amount of waste we generate.
Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe—lessons for the future
Marlies Noordzij, Björn Meijers, Ron T Gansevoort, Adrian Covic, Raphaël Duivenvoorden, Luuk B Hilbrands, Marc H Hemmelder, Kitty J Jager, Geir Mjoen, Ionut Nistor, Ekaterina Parshina, Giuseppina Pessolano, Serhan Tuglular, Priya Vart, Luca Zanoli, Casper F M Franssen, ERACODA collaborators
doi : 10.1093/ckj/sfac253
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 662–675
Early reports on the pandemic nature of coronavirus disease 2019 (COVID-19) directed the nephrology community to develop infection prevention and control (IPC) guidance. We aimed to make an inventory of strategies that dialysis centres followed to prevent infection with COVID-19 in the first pandemic wave.
War in Ukraine and dialysis treatment: human suffering and organizational challenges
Volodymyr Novakivskyy, Roman Shurduk, Inna Grin, Taisiia Tkachenko, Nataliia Pavlenko, Anastasiia Hrynevych, Jeffrey L Hymes, Franklin W Maddux, Stefano Stuard
doi : 10.1093/ckj/sfad003
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 676–683
In January 2021, there were 9648 patients in Ukraine on kidney replacement therapy, including 8717 on extracorporeal therapies and 931 on peritoneal dialysis. On 24 February 2022, foreign troops entered the territory of Ukraine.
Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution
Mehmet Kanbay, Sidar Copur, Berk Mizrak, Alberto Ortiz, Maria Jose Soler
doi : 10.1093/ckj/sfac270
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 684–692
Acute kidney injury (AKI) is common in hospitalized patients while common risk factors for the development of AKI include postoperative settings, patients with baseline chronic kidney disease (CKD) or congestive heart failure.
Combining neutrophil and macrophage biomarkers to detect active disease in ANCA vasculitis: a combinatory model of calprotectin and urine CD163
Paula Anton-Pampols, Laura MartÃnez Valenzuela, Loreto Fernández Lorente, Maria Quero Ramos, Francisco Gómez Preciado, Irene MartÃn Capón, Francisco Morandeira, JoaquÃn Manrique Escola, Xavier Fulladosa, Josep Maria Cruzado, Joan Torras, Juliana Draibe
doi : 10.1093/ckj/sfac257
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 693–700
CD163 and calprotectin have been proposed as biomarkers of active renal vasculitis. This study aimed to determine whether the combination of serum/urine calprotectin (s/uCalprotectin) and urinary soluble CD163 (suCD163) increases their individual performance as activity biomarkers.
Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study
Orit Kliuk-Ben Bassat, Meir Schechter, Natalia Ashtamker, Ilan Yanuv, Aliza Rozenberg, Boaz Hirshberg, Ayelet Grupper, Nachum Vaisman, Silviu Brill, Ofri Mosenzon
doi : 10.1093/ckj/sfac275
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 701–710
Chronic pain is prevalent but difficult to treat in patients undergoing hemodialysis (HD). Effective and safe analgesics are limited in this patient population.
The metabolites of de novo NAD+ synthesis are a valuable predictor of acute kidney injury
Yujia Wang, Yi Guan, Qionghong Xie, Weiyuan Gong, Jianhua Li, Tong Chen, Yanfang Xu, Ning Xu, Shaohao Chen, Mo Chen, Zhengxin Wang, Chuan-Ming Hao
doi : 10.1093/ckj/sfac262
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 711–721
Acute kidney injury (AKI) is often iatrogenic and potentially preventable. Reduced renal nicotinamide adenine dinucleotide (NAD+) is reported to increase the susceptibility of AKI.
Fabry disease with atypical phenotype identified by massively parallel sequencing in early-onset kidney failure
Amber de Haan, Chantal F Morel, Mark Eijgelsheim, Margriet F C de Jong, Jan Broekroelofs, Liffert Vogt, Nine V A M Knoers, Martin H de Borst
doi : 10.1093/ckj/sfac269
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 722–726
The cause of chronic kidney disease (CKD) remains unknown in ∼20% of patients with kidney failure. Massively parallel sequencing (MPS) can be a valuable diagnostic tool in patients with unexplained CKD, with a diagnostic yield of 12%–56%. Here, we report the use of MPS to establish a genetic diagnosis in a 24-year-old index patient who presented with hypertension, nephrotic-range proteinuria and kidney failure of unknown origin.
Interaction effect between fasting plasma glucose and lipid profiles on mortality of peritoneal dialysis patients
Yiping Xu, Zhong Zhong, Yi Li, Zhijian Li, Yi Zhou, Zhibin Li, Haiping Mao
doi : 10.1093/ckj/sfac266
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 727–734
Peritoneal dialysis (PD) patients have a high risk of abnormal glucose and lipids metabolism.
Time-averaged concentration estimation of uraemic toxins with different removal kinetics: a novel approach based on intradialytic spent dialysate measurements
Joosep Paats, Annika Adoberg, Jürgen Arund, Annemieke Dhondt, Anders Fernström, Ivo Fridolin, Griet Glorieux, Emilio Gonzalez-Parra, Jana Holmar, Liisi Leis, Merike Luman, Vanessa Maria Perez-Gomez, Kristjan Pilt, Didier Sanchez-Ospina, Mårten Segelmark, Fredrik Uhlin, Alberto Ortiz
doi : 10.1093/ckj/sfac273
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 735–744
Kt/Vurea is the most used marker to estimate dialysis adequacy; however, it does not reflect the removal of many other uraemic toxins, and a new approach is needed.
Disparities in treatment and outcome of kidney replacement therapy in children with comorbidities: an ESPN/ERA Registry study
Raphael Schild, Simeon Dupont, Jérôme Harambat, Enrico Vidal, Ayşe Balat, Csaba Bereczki, Beata Bieniaś, Per Brandström, Francoise Broux, Silvia Consolo, Ivana Gojkovic, Jaap W Groothoff, Kristine Hommel, Holger Hubmann, Fiona E M Braddon, Tatiana E Pankratenko, Fotios Papachristou, Lucy A Plumb, Ludmila Podracka, Sylwester Prokurat, Anna Bjerre, Carolina Cordinhã, Juuso Tainio, Enkelejda Shkurti, Giuseppina Spartà , Karel Vondrak, Kitty J Jager, Jun Oh, Marjolein Bonthuis
doi : 10.1093/ckj/sfad008
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 745–755
Data on comorbidities in children on kidney replacement therapy (KRT) are scarce. Considering their high relevance for prognosis and treatment, this study aims to analyse the prevalence and implications of comorbidities in European children on KRT.
Backtracking cryptic recurrence of esophageal cancer from membranous nephropathy: the detection of glomerular NELL-1 and IgG4
Shuai Zhou, FuLei Meng, ShuLing Yue, Hang Li, LiHong Zhang, Tao Wang
doi : 10.1093/ckj/sfac261
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 756–759
We reported the detection of neural epidermal growth factor-like 1 (NELL-1) and immunoglobulin G4 (IgG4) on glomerular capillary wall in membrane nephropathy (MN), which led to the discovery of early post-operative recurrence of esophageal squamous cell cancer (ESCC) in a 68-year-old man.
Pseudo-acute kidney injury secondary to tepotinib
Veerle Wijtvliet, Laurence Roosens, Charlotte De Bondt, Annelies Janssens, Daniel Abramowicz
doi : 10.1093/ckj/sfac180
Clinical Kidney Journal, Volume 16, Issue 4, April 2023, Pages 760–761
